Furazolidone
Furoxone (furazolidone) is a small molecule pharmaceutical. Furazolidone was first approved as Furoxone on 1982-01-01. It is used to treat animal salmonella infections, bacillary dysentery, cholera, diarrhea, and enteritis amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| animal salmonella infections | — | D012481 | — |
| bacillary dysentery | — | D004405 | A03 |
| cholera | — | D002771 | A00 |
| diarrhea | HP_0002014 | D003967 | R19.7 |
| enteritis | — | D004751 | K52.9 |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| giardiasis | DOID_10718 | D005873 | A07.1 |
| proteus infections | EFO_1001130 | D011512 | — |
| staphylococcal infections | — | D013203 | A49.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AX: Other gynecological antiinfectives and antiseptics in atc
— G01AX06: Furazolidone
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AB: Nitroimidazole derivatives, antiprotozoal agents against amoebiasis and other protozoal diseases
— P01AB51: Metronidazole and furazolidone
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | — | 1 |
| Peritoneal dialysis | D010530 | — | — | 1 | — | — | 1 | ||
| Continuous ambulatory peritoneal dialysis | D010531 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Weight loss | D015431 | HP_0001824 | — | 1 | — | — | — | 1 | |
| Cachexia | D002100 | HP_0004326 | R64 | — | 1 | — | — | — | 1 |
| Anorexia | D000855 | HP_0002039 | R63.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FURAZOLIDONE |
| INN | furazolidone |
| Description | Furazolidone is a member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera. It has a role as an EC 1.4.3.4 (monoamine oxidase) inhibitor, an antitrichomonal drug, an antiinfective agent and an antibacterial drug. It is a member of oxazolidines and a nitrofuran antibiotic. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1 |
Identifiers
| PDB | — |
| CAS-ID | 67-45-8 |
| RxCUI | 4601 |
| ChEMBL ID | CHEMBL1103 |
| ChEBI ID | — |
| PubChem CID | 5323714 |
| DrugBank | DB00614 |
| UNII ID | 5J9CPU3RE0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,289 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more